Masthead

GeoMx® Immune Pathways Panel

Masthead

Helping Your Research

Targeted Content for Cancer Biology

The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.

Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).

How it Works

About
GeoMx® Immune Pathways Panel
About

The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.

  • Curated content designed for immuno-oncology research
  • Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
  • Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
  • Compatible with RNAscope® and antibody morphology markers for tissue imaging
  • Customizable with up to 10 additional targets of interest
  • For use with nCounter readout and compatible with DSP Data Center
GeoMx® Immune Pathways Panel

Curated Content for Immuno-Oncology

The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.

  • Profile the global immune response
  • Assess microenvironment immune activity
  • Quantify tumor reactivity
  • Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade

Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Next-Generation Digital Histopathology of the Tumor Microenvironment.

Progress in cancer research is substantially dependent on innovative technologies that permit a concerted analysis of the tumor microenvironment and the cellular phenotypes resulting from somatic mutations and post-translational modifications. In view of a large number of genes, multiplied by differential splicing as well as post-translational protein modifications, the ability to identify and quantify the actual phenotypes of individual cell populations in situ, i.

Applicability of spatial transcriptional profiling to cancer research.

Spatial transcriptional profiling provides gene expression information within the important anatomical context of tissue architecture. This approach is well suited to characterizing solid tumors, which develop within a complex landscape of malignant cells, immune cells, and stroma.

Related Resources

See All Resources
Product Bulletin GeoMx RNA Panel for IO – Product Bulletin
Brochure/eBook GeoMx DSP – Brochure
Report DSP TAP Sample Report
Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us